CLINICAL TRIALS PROFILE FOR DIAZOXIDE

All Clinical Trials for diazoxide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004825 ↗	Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism	Completed	Children's Hospital of Philadelphia	N/A	1998-05-01	OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism. II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population. III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.
NCT00004825 ↗	Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism	Completed	FDA Office of Orphan Products Development	N/A	1998-05-01	OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism. II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population. III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.
NCT00131755 ↗	Efficacy of Diazoxide in Type 1 Diabetes	Completed	Grill, Valdemar, M.D.	Phase 4	2005-02-01	The purpose of this study is to find out if Diazoxide can partly retain insulin production in newly diagnosed type 1 diabetes patients.
NCT00151684 ↗	Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men	Completed	Rijnstate Hospital	Phase 2	2004-11-01	The purpose of this study is to explore diazoxide efficacy in treatment of obese men and assessment of maximal insulin suppression in obese men without hyperglycaemia. Obesity is associated with markedly elevated plasma insulin levels throughout the day. The concept is that obese subjects predominantly develop lean tissue resistance against the glucoregulatory actions of insulin, but remain relatively sensitive to the lipogenic and antilipolytic effects of insulin in adipose tissue. According to this theory, suppression of hyperinsulinism by diazoxide, a well known inhibitor of glucose stimulated insulin secretion, might be useful to treat obesity because it will help to reverse the process of lipid storage.
NCT00184821 ↗	Ischemic Injury and Ischemic Preconditioning in Diabetes	Completed	Dutch Diabetes Fund		2004-06-01	In this proof-of-concept study, forearm vulnerability to ischemic exercise is studied in patients with type 1 diabetes mellitus with and without prior ischemic preconditioning (short period of ischemia that protects against subsequent ischemic exercise). Annexin A5 scintigraphy is used to quantify subtle signs of mild and reversible forearm injury that results from ischemic exercise. The following hypotheses are tested: 1. Patients with type 1 diabetes are not more vulnerable to ischemic injury as compared with previously studied healthy volunteers. 2. Ischemic preconidtioning is still present in patients with type 1 diabetes. Depending on the validity of hypothesis 2, the effect of short pharmacological interventions are studied on vulnerability to forearm ischemia/reperfusion injury in the absence or presence of local forearm ischemic preconditioning.
NCT00184821 ↗	Ischemic Injury and Ischemic Preconditioning in Diabetes	Completed	Radboud University		2004-06-01	In this proof-of-concept study, forearm vulnerability to ischemic exercise is studied in patients with type 1 diabetes mellitus with and without prior ischemic preconditioning (short period of ischemia that protects against subsequent ischemic exercise). Annexin A5 scintigraphy is used to quantify subtle signs of mild and reversible forearm injury that results from ischemic exercise. The following hypotheses are tested: 1. Patients with type 1 diabetes are not more vulnerable to ischemic injury as compared with previously studied healthy volunteers. 2. Ischemic preconidtioning is still present in patients with type 1 diabetes. Depending on the validity of hypothesis 2, the effect of short pharmacological interventions are studied on vulnerability to forearm ischemia/reperfusion injury in the absence or presence of local forearm ischemic preconditioning.

Clinical Trial Conditions for diazoxide

Condition Name

Condition Name for diazoxide
Intervention	Trials
Prader-Willi Syndrome	6
Hypertriglyceridemia	5
Glucose, High Blood	4
Glucose Metabolism Disorders	3

Condition MeSH

Condition MeSH for diazoxide
Intervention	Trials
Hyperinsulinism	8
Hypoglycemia	7
Syndrome	7
Congenital Hyperinsulinism	6

Clinical Trial Locations for diazoxide

Trials by Country

Trials by Country for diazoxide
Location	Trials
United States	64
United Kingdom	7
Netherlands	3
France	2
Canada	2

Trials by US State

Trials by US State for diazoxide
Location	Trials
New York	9
California	7
Maryland	4
Colorado	3
Texas	3

Clinical Trial Progress for diazoxide

Clinical Trial Phase

Clinical Trial Phase for diazoxide
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	6
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for diazoxide
Clinical Trial Phase	Trials
Completed	21
Withdrawn	5
Not yet recruiting	4

Clinical Trial Sponsors for diazoxide

Sponsor Name

Sponsor Name for diazoxide
Sponsor	Trials
Essentialis, Inc.	8
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	5
Albert Einstein College of Medicine	5

Sponsor Type

Sponsor Type for diazoxide
Sponsor	Trials
Other	40
Industry	19
NIH	11